Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established...
Oblenio Bio
Nanjing Leads Biolabs and Aditum Bio Launch Oblenio Bio with Focus on CD19 Tri-Specific Antibody
China-based Nanjing Leads Biolabs Co., Ltd and venture capital firm Aditum Bio have announced the...